• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Finance

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

November 10, 2021 Microbiome Times

SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate […]

Finance

ADM to Acquire Deerland Probiotics & Enzymes

November 5, 2021 Microbiome Times

ADM (NYSE: ADM), a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland […]

Pharma & Human Health

Probiotics : A Helping Hand Toward a Fitter Life

October 27, 2021 Microbiome Times

For a long time, consumers have associated metabolic health with a healthy weight, but it goes far beyond that. Metabolic health is not about looking good, it is about being healthy, and it involves having […]

Pharma & Human Health

New study characterizes the gut virome

October 25, 2021 Microbiome Times

A new study has added numerous previously uncharacterized viral genomes and genes to the ever-increasing worldwide pool of human gut viromes. The study, published in mSystems, an open-access journal of the American Society for Microbiology, […]

Pharma & Human Health

Solarea Bio Announces Licensing Agreement with ADM

October 20, 2021 Microbiome Times

Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, announced it has signed a technology licensing agreement with global nutrition leader ADM (NYSE: ADM). Solarea Bio has developed […]

Finance

Axial Therapeutics Raises $37.25 Million in Series C Financing

October 13, 2021 Microbiome Times

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, […]

Pharma & Human Health

Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology

October 11, 2021 Microbiome Times

Intralytix, Inc. announced that its food safety product, CampyShield™, has received GRAS (Generally Recognized as Safe) recognition from the Food and Drug Administration (FDA), GRAS No: GRN 000966. CampyShield™ is a non-chemical antimicrobial preparation containing […]

Pharma & Human Health

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

October 5, 2021 Microbiome Times

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase 2 clinical trial of VE303, an orally administered investigational live […]

Pharma & Human Health

Changing requirements for anaerobic culture equipment in microbiome research and product development

October 5, 2021 Microbiome Times

Improved growth of certain organisms (now known to be bacteria) in the absence of oxygen was conclusively demonstrated by Louis Pasteur in the 1860s.  Catalytic removal of oxygen from the incubation atmosphere, allowing surface growth […]

Pharma & Human Health

L’Oréal Singapore and NTU Singapore set up joint lab hosted by SCELSE for deeper exploration of skin and scalp microbiomes

October 4, 2021 Microbiome Times

Nanyang Technological University, Singapore (NTU Singapore) and L’Oréal Singapore today launched a new joint laboratory hosted by the Singapore Centre for Environmental Life Sciences Engineering (SCELSE), to conduct research on the community of bacteria, fungi, […]

Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

September 30, 2021 Microbiome Times

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The […]

Posts navigation

« 1 … 26 27 28 … 77 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter